Shots:
- The US FDA has approved Yuvezzi (carbachol & brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, for the treatment of presbyopia in adults; commercially available by Q2’26
- Approval was backed by 2 P-III (BRIO I & BRIO II) trials (n>800), with BRIO I showing superior benefit vs individual actives & BRIO II meeting all 1EPs, showing statistically significant ≥3-line BUNVA improvement over 8hrs. without ≥1-line BUDVA loss vs vehicle
- Yuvezzi is a dual-agent eye drop that enhances near visual acuity & depth of focus by inducing pupillary constriction & creating a pinhole effect
Ref: Businesswire | Image: Tenpoint | Press Release
Related News: GSK’s Arexvy Receives the EC Approval to Prevent Respiratory Syncytial Virus (RSV) Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
